9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134

Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134

Estimated reading time: < 1 min

Condition: Malignant Pleural Mesothelioma

Estimated Enrollment: 60

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: 1-Year Progression Free Survival,  ,  ,

Interventions: WT-1-vaccine Montanide + GM-CSF, Montanide adjuvant + GM-CSF

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double (Participant, Investigator),Primary Purpose: Treatment

Primary Completion Date: April 2020

Completion Date: April 2021

Last  Posted Date: May 10, 2019

Location: Memorial Sloan Kettering Cancer Center, New York, New York, United States

Website Link: https://ClinicalTrials.gov/show/NCT01890980

Was this article helpful?
Dislike 0